Rituximab Plus Bendamustine: Superior to R-CHOP for Grade 3A Follicular Lymphoma

Share this content:
The median PFS was significantly longer in the R-B arm: 15.0 years compared with 11.7 years in the R-CHOP arm.
The median PFS was significantly longer in the R-B arm: 15.0 years compared with 11.7 years in the R-CHOP arm.

Rituximab plus bendamustine (R-B) is a well-tolerated first-line therapy compared with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHOP), and leads to improved progression-free survival (PFS) among patients with grade 3A follicular lymphoma (FL3A), according to a study published in The Oncologist.1

Previous studies demonstrated that R-B is superior to R-CHOP and rituximab, cyclophosphamide, vincristine, and prednisolone (R-CVP) — 2 first-line options for FL — but its efficacy specifically for FL3A was previously unestablished.

For this retrospective study, researchers assessed the outcomes of 132 patients with FL3A who were treated in the first-line with R-B or R-CHOP for up to 6 cycles. A greater portion of patients in the R-B arm were characterized with worse prognostic factors such as bone marrow involvement and Ki67 expression greater than 30% compared with patients in the R-CHOP arm (59% vs 11%, respectively; P < .001; 45% vs 19%, respectively; P < .001), but there were no significant differences in BCL2 expression with or without BCL6 co-expression between the arms. Follow-up visits were conducted 1 month after therapy completion and then every 3 to 6 months for 5 years to evaluate response.

The average follow-up was 15.2 years vs 14.8 years for the R-B vs the R-CHOP arm, respectively. The median PFS was significantly longer in the R-B arm: 15.0 years compared with 11.7 years in the R-CHOP arm (P = .03). Median OS did not differ significantly and was not reached in either treatment arm.

R-B had a superior safety profile compared with R-CHOP, with improvements in the rates of grade 1 to 2 and 3 to 4 neutropenia (6% vs 30%, respectively; P < .001; 10% vs 26%, respectively; P < .01) — which led to higher rates of infection in the R-CHOP arm (35% vs 5%, respectively; P < .006) — as well as improved rates of anemia, thrombocytopenia, alopecia, peripheral neuropathy, and drug-associated erythematous skin reactions.

Dose reductions also occurred less frequently in the R-B arm compared with the R-CHOP arm (1% vs 12%, respectively; P =.004).

Reference

  1. Mondello P, Steiner N, Willenbacher W, et al. Bendamustine plus rituximab versus R-CHOP as first-line treatment for patients with follicular lymphoma grade 3A: evidence from a multicenter, retrospective study. Oncologist. 2017 Jan 9. doi: 10.1634/theoncologist.2017-0037 [Epub online ahead of print] 

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs